More than half of regular opioid users suffer from arthritis. Here are three tips to talk to your patients about opioid use and alternative pain management…
Trump Says He Will Allow States to Import Prescription Drugs to Lower Costs
WASHINGTON (Reuters)—U.S. President Donald Trump said on Friday, Nov. 22, he will soon release a plan to let Florida and other states import prescription medicines to combat high drug prices. He blasted the Democrat-led U.S. House of Representatives for not going far enough in a drug-pricing bill. “We will soon be putting more options on…
Rituximab-abbs Available in the U.S.; Plus Upadacitinib in Phase 3 Trials for PsA
Rituximab-abbs, which is biosimilar to rituximab, is now available in the U.S. to treat specific cancers…
FDA Action on Loperamide Misuse; Plus Phase 1 Trials for BAT2506 Biosimilar Begin
The FDA has limited the package size of some over-the-counter loperamide products to prevent its potential misuse and abuse…
Scottish Medicines Consortium Recommends Risankizumab; Plus Real-World Data on Secukinumab
The Scottish Medicines Consortium has released a detailed advice document recommending risankizumab for treating adults with psoriasis…
FDA Approves Rituximab for Children with GPA & MPA
Intravenous rituximab can now be used to treat pediatric patients with GPA and MPA as young as two years old…
Iguratimod May Hold Promise for Treating Autoimmune Disease
NEW YORK (Reuters Health)—Iguratimod, a disease-modifying drug marketed in China and Japan, appears to be effective in treating rheumatoid arthritis (RA) and possibly other autoimmune diseases, while protecting against adverse bone effects, researchers from China say. Iguratimod is a methane sulfonanilide compound that influences several anti-inflammatory and immune-modulatory pathways and has an anabolic effect on…
UnitedHealthcare Delays Policy Changes Affecting Physician-Administered Treatments
Changes announced at the beginning of October have now been delayed for Actemra, Benlysta, Cimzia, Orencia and Simponi Aria, but changes to the Stelara policy remain in effect.
Clinical Insights into Gout Management: Rheumatology Drugs at a Glance Pt. 4
Three clinical experts on gout offer their insights into common management errors, clinical pearls, new safety data from the FDA and the role of biologic therapies in the management of gout.
Humira, Rituxan Top List of U.S. Drugs with Biggest Price Increases
NEW YORK (Reuters)—AbbVie Inc.’s rheumatoid arthritis drug Humira (adalimumab) and Roche Holding AG’s cancer drug Rituxan (rituximab) topped a list of seven treatments whose combined 2017 and 2018 price hikes accounted for a $5.1 billion increase in U.S. spending, a report released on Tuesday showed.1 The price hikes were more than twice the rate of…
- « Previous Page
- 1
- …
- 35
- 36
- 37
- 38
- 39
- …
- 125
- Next Page »